-
Spyre Therapeutics Inc NASDAQ:SYRE Combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease. On Nov. 27, 2023, company announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol "SYRE".
Location: | Website: spyre.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
404.4M
Cash
603.1M
Avg Qtr Burn
-39.35M
Short % of Float
25.20%
Insider Ownership
8.72%
Institutional Own.
-
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SPY001 (α4β7) Details Crohns disease, Inflammatory bowel disease | Phase 2 Initiation | |
SPY003 Details N/A | Phase 1 Data readout | |
SPY002 (TL1A) Details Inflammatory bowel disease | Phase 1 Data readout |